Table 2.
Study on the correlation between clinical liver cancer and the total number of Nanog + CSCs.
| Clinical Characteristics | Nanog≤6.7 | Nanog>6.7 | P |
|---|---|---|---|
| Sex (Male/Female) | 92/13 | 49/6 | 0.785 |
| Age (≤60/>60 years) | 78/27 | 45/10 | 0.283 |
| Age(≤39/40-49/≥50) | 5/33/67 | 9/17/29 | 0.047 |
| Tumor Size (≤5/>5 cm) | 70/35 | 27/28 | 0.031 |
| Tumor Number (≤1/>1) | 79/26 | 43/12 | 0.678 |
| Differentiation (H/M/L) | 18/65/22 | 5/38/12 | 0.381 |
| BCLC Stage (A/B+C) | 68/37 | 25/30 | 0.019 |
| Metastasis (Yes/No) | 14/91 | 7/48 | 0.914 |
| AFP (≤400/>400 μg/L) | 66/39 | 38/17 | 0.432 |
| PIVKA (≤400/>400 μg/L) | 61/44 | 29/26 | 0.516 |
| Vascular Invasion (+/-) | 34/71 | 25/30 | 0.104 |
| MVI (Yes/No) | 29/76 | 20/35 | 0.254 |
| MVD (Yes/No) | 17/88 | 11/44 | 0.547 |
| HBsAg (+/-) | 90/15 | 53/2 | 0.038 |
| CTC (≤13.3/>13.3) | 96/9 | 17/38 | 0.0001 |
| Direct Bilirubin (≤4/>4) | 49/56 | 21/34 | 0.304 |
| Total Bilirubin (≤18/>18) | 60/45 | 31/24 | 0.925 |
| ALT (≤84/>84 IU/L) | 92/13 | 42/13 | 0.067 |
| TNM (I-II/III-IV) | 76/29 | 37/18 | 0.5 |
| Edmondson Stage (I-II/III-IV) | 71/34 | 37/18 | 0.965 |
| HBV DNA (≤100/>100) | 67/38 | 22/33 | 0.004 |
| NLR (≤1.77/>1.77) | 24/14 | 81/41 | 0.714 |
| INR (≤1/>1) | 38/67 | 19/36 | 0.937 |
| APRI (≤1/>1) | 95/10 | 49/6 | 0.781 |
| HB (≤120/>120) | 12/93 | 5/50 | 0.649 |
| Neutrophil (≤4/>4) | 80/25 | 35/20 | 0.093 |
| Lymphocyte (≤1/>1) | 34/71 | 10/45 | 0.056 |
| PT (≤12/>12) | 57/48 | 29/26 | 0.851 |
| PLT (≤100/>100) | 33/72 | 12/43 | 0.199 |
| AST (≤45/>45) | 67/38 | 27/28 | 0.072 |
| ALB (≤35/>35) | 9/96 | 5/50 | 0.912 |
| ICG (≤10/>10%) | 89/16 | 47/8 | 0.9072 |
P value < 0.05 was considered statistically significant (Pearson Correlation Coefficient); INR, International Normalized Ratio; APRI, AST to platelet ratio index; HB, hemoglobin; PT, prothrombin time; PLT, platelets; AST, glutamic oxaloacetic transaminase; ALB, albumin; ICG, indocyanine green. Bold font is used to describe p<0.05, which is statistically significant.